PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33440483-3	2016	Growth factor binding ability of the native sulfated glycosaminoglycans can be incorporated into the synthetic scaffold matrix through functionalization with specific chemical moieties.	Glycosaminoglycans	53-71	myotrophin	Rattus norvegicus	0-13	
2607320-9	1989	Transforming growth factor beta (greater than 10 pmol/l) inhibited foetal calf serum (Dulbecco"s modification of Eagle"s medium with a fraction of foetal calf serum of 0.1) and epidermal growth factor stimulated proliferation but enhanced the synthesis of sulphated glycosaminoglycans about 2-fold.	Glycosaminoglycans	266-284	myotrophin	Rattus norvegicus	13-26	
2607320-9	1989	Transforming growth factor beta (greater than 10 pmol/l) inhibited foetal calf serum (Dulbecco"s modification of Eagle"s medium with a fraction of foetal calf serum of 0.1) and epidermal growth factor stimulated proliferation but enhanced the synthesis of sulphated glycosaminoglycans about 2-fold.	Glycosaminoglycans	266-284	myotrophin	Rattus norvegicus	187-200	
33662819-0	2021	Histologic evaluation of therapeutic responses in ischemic myocardium elicited by dual growth factor delivery from composite glycosaminoglycan hydrogels.	Glycosaminoglycans	125-142	myotrophin	Rattus norvegicus	87-100	
33754692-0	2021	Injectable Glycosaminoglycan-Based Cryogels from Well-Defined Microscale Templates for Local Growth Factor Delivery.	Glycosaminoglycans	11-28	myotrophin	Rattus norvegicus	93-106